Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 25, 2020
Daily News
May 25, 2020
- June Approval Likely for Entresto as It Clears Key Panel; HFpEF Use OK’ed Too
May 25, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- 90% of Drug Promotion Shifted to Remote Tools; Prudent Attitude Needed for New Launches amid COVID-19: IQVIA Official
May 25, 2020
- PMDA Reviewing Safety Risks for Avastin, Memary
May 25, 2020
- Enhertu Gets US FDA’s Orphan Status for Gastric Cancer
May 25, 2020
- US FDA Approves Sunovion’s Apomorphine Sublingual Film for Parkinson’s
May 25, 2020
- AMED to Fund 4 Company-Led COVID-19 Vaccine Development Projects
May 25, 2020
- Bayer Files Japan NDA for Larotrectinib in NTRK-Positive Solid Tumors
May 25, 2020
- Avigan Not Yet Filed in Japan, but Govt Still Seeks Approval by Month-End: Kato
May 25, 2020
- Daiichi Sankyo Launches PI for DS-6157 for GIST; 5th ADC Entered in Clinical Stage
May 25, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…